You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

120 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
ODB - General Benefit
    procarbazine
ODB - General Benefit
    prednisone
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Palliative
Funding:
ODB - General Benefit
    prednisone
Jan 2018
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Palliative
Funding:
ODB - General Benefit
    cyclophosphamide - oral tablets
ODB - General Benefit
    prednisone
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Jul 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    mercaptopurine
New Drug Funding Program
    Pegaspargase (Outpatient) - Adult Acute Lymphoblastic Leukemia (ALL) Lymphoblastic Lymphoma Mixed or Biphenotypic Leukemia
New Drug Funding Program
    Calaspargase Pegol (Outpatient) - Newly Diagnosed Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed_Biphenotypic Leukemia
Nov 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell
Intent: Curative
Funding:
ODB - General Benefit
    prednisone
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    prednisone
Nov 2023
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    prednisone
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    prednisone
ODB - General Benefit
    cyclophosphamide - oral tablets
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    chlorambucil
Regimen
Cancer Type:
Hematologic, 
Rare Diseases, 
Sarcoma
Intent: Palliative
Funding:
ODB - General Benefit
    prednisone
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade, 
Lymphoma - T-cell
Intent: Curative, Palliative
Funding:
New Drug Funding Program
    Brentuximab Vedotin - In Combination with Chemotherapy for Previously Untreated Peripheral T-cell Lymphoma (PTCL)
ODB - General Benefit
    prednisone
Jan 2022

Pages